CA2523870A1 - Claudins' underexpression as markers of tumor metastasis - Google Patents

Claudins' underexpression as markers of tumor metastasis Download PDF

Info

Publication number
CA2523870A1
CA2523870A1 CA002523870A CA2523870A CA2523870A1 CA 2523870 A1 CA2523870 A1 CA 2523870A1 CA 002523870 A CA002523870 A CA 002523870A CA 2523870 A CA2523870 A CA 2523870A CA 2523870 A1 CA2523870 A1 CA 2523870A1
Authority
CA
Canada
Prior art keywords
claudin
cell
kit
antibody
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002523870A
Other languages
English (en)
French (fr)
Inventor
Steven C. Quay
Kunyuan Cui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marina Biotech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2523870A1 publication Critical patent/CA2523870A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002523870A 2003-04-30 2004-04-30 Claudins' underexpression as markers of tumor metastasis Abandoned CA2523870A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46690503P 2003-04-30 2003-04-30
US60/466,905 2003-04-30
PCT/US2004/013436 WO2004098647A2 (en) 2003-04-30 2004-04-30 Claudins’ underexpression as markers of tumor metastasis

Publications (1)

Publication Number Publication Date
CA2523870A1 true CA2523870A1 (en) 2004-11-18

Family

ID=33434995

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002523870A Abandoned CA2523870A1 (en) 2003-04-30 2004-04-30 Claudins' underexpression as markers of tumor metastasis

Country Status (8)

Country Link
US (1) US20040253211A1 (enExample)
EP (1) EP1620732A2 (enExample)
JP (1) JP2006525351A (enExample)
CN (1) CN100575955C (enExample)
CA (1) CA2523870A1 (enExample)
MX (1) MXPA05011644A (enExample)
NO (1) NO20055449L (enExample)
WO (1) WO2004098647A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061739A1 (fr) 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2672581A1 (en) * 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
EP2138576A4 (en) * 2007-03-16 2011-02-23 Kyowa Hakko Kirin Co Ltd ANTI-CLAUDIN-4 ANTIBODY
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
KR101741898B1 (ko) 2015-05-27 2017-06-01 울산대학교 산학협력단 Claudin 7을 포함하는 방사선 반응성 위암 진단용 바이오마커 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744166A (en) * 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
US5554388A (en) * 1989-02-25 1996-09-10 Danbiosyst Uk Limited Systemic drug delivery compositions comprising a polycationi substance
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
GB9310412D0 (en) * 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
GB9412394D0 (en) * 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
GB9419979D0 (en) * 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
GB9522351D0 (en) * 1995-11-01 1996-01-03 Medeva Holdings Bv Vaccine compositions
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
WO1998000013A1 (en) * 1996-06-28 1998-01-08 The Regents Of The University Of California Enhancement of cancer cell death
WO1999027905A1 (en) * 1997-12-02 1999-06-10 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Compositions for nasal administration
GB9726916D0 (en) * 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
US6248864B1 (en) * 1997-12-31 2001-06-19 Adherex Technologies, Inc. Compounds and methods and modulating tissue permeability
US7279294B2 (en) * 2000-04-03 2007-10-09 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services, Nih Tumor markers in ovarian cancer
CN1234727C (zh) * 2000-06-01 2006-01-04 北京双鹭药业股份有限公司 人胸腺素α原基因突变体合成、表达及应用
WO2003069307A2 (en) * 2002-02-14 2003-08-21 The Johns Hopkins University School Of Medicine Claudins, markers for diagnosis, prognosis and therapy of breast, bone, brain cancer

Also Published As

Publication number Publication date
CN1816745A (zh) 2006-08-09
MXPA05011644A (es) 2005-12-15
WO2004098647A2 (en) 2004-11-18
JP2006525351A (ja) 2006-11-09
CN100575955C (zh) 2009-12-30
US20040253211A1 (en) 2004-12-16
NO20055449D0 (no) 2005-11-17
EP1620732A2 (en) 2006-02-01
WO2004098647A3 (en) 2005-03-03
NO20055449L (no) 2006-01-26

Similar Documents

Publication Publication Date Title
US7279294B2 (en) Tumor markers in ovarian cancer
EP1824997B1 (en) Genetic alteration useful for the response prediction of malignant neoplasia to taxane-based medical treatment
CA2500470A1 (en) Method for diagnosing chronic myeloid leukemia
JP2001514012A (ja) 播種・微小転移性癌細胞を特性化する方法
JP2002514076A (ja) 散在性腫瘍細胞の検出のための新規プライマー及び方法
US20030013099A1 (en) Genes regulated by DNA methylation in colon tumors
EP1612281A2 (en) Methods for assessing patients with acute myeloid leukemia
US20110236396A1 (en) Methods and compositions for diagnosing and treating a colorectal adenocarcinoma
JP2014020930A (ja) 膵癌診断及び治療効果予測判定バイオマーカー
US20040253211A1 (en) Method for diagnosing and treating cancer
US7803532B2 (en) Method for the diagnosis of lymphoproliferative diseases
US7776519B2 (en) Use of the slug gene, or of the transcription or expression products thereof in the detection and/or treatment of cancerous cells
JP2012147796A (ja) 肺癌の診断及び治療方法
WO2003097872A2 (en) G - protein coupled receptor marker molecules associated with colorectal lesions
US20090298766A1 (en) Detection and treatment of cancers
US20050100897A1 (en) NFAT transcription factors in tumor progression
JP2003528630A (ja) ヒト遺伝子および発現産物
KR101104105B1 (ko) 대장암 진단용 조성물 및 그 용도
JP5557139B2 (ja) 食道癌の検出又は予後の予測のための方法及び食道癌抑制剤
KR20110036559A (ko) 대장암 진단용 조성물 및 그 용도
KR20110036560A (ko) 대장암 진단용 조성물 및 그 용도

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued